The Latest Cardiac and Vascular News
FRANKLIN LAKES, N.J., March 31, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Alberto Mas has informed the company of his intent to retire from BD, effective at the end of the company’s fiscal year on Sept. 30, 2022. Mas, 60, is currently executive vice president and president of the […]
FRANKLIN LAKES, N.J., March 30, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced the early results and pricing terms of Morgan Stanley & Co. LLC’s (“Morgan Stanley”) previously announced cash tender offers (each, an “Offer” and collectively, the “Offers”) for the notes set forth below (collectively, the “Notes” […]
Digital Health Pioneer to Focus on External Innovation; Becomes Co-Chair of BD Scientific Advisory Board FRANKLIN LAKES, N.J., Nov. 29, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Joseph M. Smith has been named senior vice president and chief scientific officer for the company, effective today. In this […]
FRANKLIN LAKES, N.J., Nov. 4, 2021 /PRNewswire/ — The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.87 per common share, an increase of 4.8% from the previous quarter. The dividend will be payable on Dec. 31, 2021 to holders of record on Dec. 10, 2021. The indicated annual dividend rate for fiscal year 2022 […]
Rotarex™ Rotational Excisional Atherectomy System is the first and only atherectomy and thrombectomy device indicated to treat in-stent restenosis in the United States FRANKLIN LAKES, N.J., Oct. 6, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance for expanded indications from the U.S. Food and Drug Administration (FDA) for […]
FRANKLIN LAKES, N.J., Aug. 19, 2021 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX) (the “Company” or “BD“) today announced the early tender results for its previously announced tender offers to purchase for cash (i) any and all of the Company’s 2.894% senior notes due 2022 and 3.300% senior notes due 2023, each listed in the first table below […]
FRANKLIN LAKES, N.J., Aug. 11, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Christopher DelOrefice has been named executive vice president and chief financial officer (CFO), effective Sept. 6, 2021. DelOrefice succeeds Christopher Reidy, 64, who announced his intent to retire from BD last week. DelOrefice, 50, will join BD from Johnson […]
FRANKLIN LAKES, N.J., Aug. 5, 2021 /PRNewswire/ — Third fiscal quarter revenues of $4.9 billion grew 26.9% on a reported basis. On a currency-neutral basis, revenues increased 22.0%. BD’s COVID-19 testing revenues were $300 million, including BD Veritor™ Plus System revenues of $212 million. Third fiscal quarter GAAP diluted earnings per share (EPS) increased 77.3% year-over-year to $1.72. Adjusted diluted EPS increased […]
– Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%. – BD’s COVID-19 testing sales were $480 million, including BD Veritor™ Plus System revenues of $290 million. – BD’s core growth led by strong growth in Medication Delivery Solutions (up 10.4%), Pharmaceutical Systems (up […]
FRANKLIN LAKES, N.J., April 29, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that enrollment has begun and the first patients have been treated in the post-market surveillance study, CONNECT-AV. CONNECT-AV is a prospective, single-arm, open-label study that will follow patients treated with the WavelinQTM EndoAVF System for 24 […]
